These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11745172)

  • 1. Protein modification during anti-viral heat-treatment bioprocessing of factor VIII concentrates, factor IX concentrates, and model proteins in the presence of sucrose.
    Smales CM; Pepper DS; James DC
    Biotechnol Bioeng; 2002 Jan; 77(1):37-48. PubMed ID: 11745172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of protein modification during anti-viral heat bioprocessing by electrospray ionization mass spectrometry.
    Smales CM; Pepper DS; James DC
    Rapid Commun Mass Spectrom; 2001; 15(5):351-6. PubMed ID: 11241766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein modification during antiviral heat bioprocessing.
    Smales CM; Pepper DS; James DC
    Biotechnol Bioeng; 2000 Jan; 67(2):177-88. PubMed ID: 10592515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of protein modification during model anti-viral heat-treatment bioprocessing of beta-lactoglobulin variant A in the presence of sucrose.
    Smales CM; Pepper DS; James DC
    Biotechnol Appl Biochem; 2000 Oct; 32(2):109-19. PubMed ID: 11001871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein modifications during antiviral heat bioprocessing and subsequent storage.
    Smales CM; Pepper DS; James DC
    Biotechnol Prog; 2001; 17(5):974-8. PubMed ID: 11587593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat treatment at 100 degrees C of factor VIII and IX coagulation factor concentrates.
    Teh LC; Woodfield DG
    Med J Aust; 1993 Sep; 159(5):355-6. PubMed ID: 8361441
    [No Abstract]   [Full Text] [Related]  

  • 8. Detection of TT virus DNA in plasma-derived clotting factor concentrates.
    Yokozaki S; Fukuda Y; Nakano I; Katano Y; Toyoda H; Takamatsu J
    Blood; 1999 Nov; 94(10):3617. PubMed ID: 10610120
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of two viral inactivation methods for the preparation of safer factor VIII and factor IX concentrates.
    Heldebrant CM; Gomperts ED; Kasper CK; McDougal JS; Friedman AE; Hwang DS; Muchmore E; Jordan S; Miller R; Sergis-Davenport E
    Transfusion; 1985; 25(6):510-5. PubMed ID: 3934800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus elimination during the recycling of chromatographic columns used during the manufacture of coagulation factors.
    Roberts PL
    Biologicals; 2014 Jul; 42(4):184-90. PubMed ID: 24981392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral safety of plasma-derived factor VIII and IX concentrates.
    Ludlam CA
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
    Roberts PL; Dunkerley C; McAuley A; Winkelman L
    Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro characterization of various heat-treated prothrombin complex concentrates (PCC).
    Yoshioka A; Nakagawa O; Uehara Y; Sakai T; Sugimoto M; Takamiya O; Tanaka I; Fukui H
    Thromb Res; 1987 Aug; 47(4):449-58. PubMed ID: 2958958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic properties and safety of recombinant factor VIII and factor IX.
    Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
    Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
    Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
    Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of monosaccharides during severe dry heat treatment of coagulation factor VIII concentrates.
    Knevelman A; de Wit HJ; Griffin B; Hart H; McIntosh RV
    Vox Sang; 1994; 66(2):96-103. PubMed ID: 8184599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
    Ikematsu S; Yorifuji H; Arai M; Fukutake K
    Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
    Mannucci PM
    Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of virucidal heat treatment on proteins in human factor VIII concentrates.
    Thomas KB; McGrath KM; Taylor M; Young IF; Herrington RW; Schiff P
    Transfusion; 1988; 28(1):8-13. PubMed ID: 3124306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.